IRIDEX (NASDAQ:IRIX) Earns Hold Rating from Analysts at StockNews.com

StockNews.com began coverage on shares of IRIDEX (NASDAQ:IRIX) in a research note issued to investors on Tuesday. The brokerage issued a hold rating on the medical equipment provider’s stock.

IRIDEX Trading Up 1.6 %

IRIX opened at $1.66 on Tuesday. The stock has a market capitalization of $27.62 million, a price-to-earnings ratio of -2.48 and a beta of 0.82. The company has a quick ratio of 0.85, a current ratio of 1.54 and a debt-to-equity ratio of 0.55. IRIDEX has a twelve month low of $1.27 and a twelve month high of $3.65. The company has a 50-day simple moving average of $1.72 and a 200 day simple moving average of $1.77.

IRIDEX (NASDAQ:IRIX) last announced its quarterly earnings data on Tuesday, November 12th. The medical equipment provider reported ($0.12) earnings per share (EPS) for the quarter. IRIDEX had a negative net margin of 22.79% and a negative return on equity of 192.95%. The firm had revenue of $11.58 million during the quarter. During the same quarter last year, the business earned ($0.11) earnings per share.

About IRIDEX

IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser systems, which are used for the treatment of retinal disorders; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser photocoagulation systems that are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments.